Publications by authors named "Yi-Han Hong"

Claim this Profile
P
p38α/S1P/SREBP2 activation by the SAM-competitive EZH2 inhibitor GSK343 limits its anticancer activity but creates a druggable vulnerability in hepatocellular carcinoma.
Pei-Ming Yang, Yi-Han Hong, Kai-Cheng Hsu, Tsang-Pai Liu

Am J Cancer Res· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
and identification of inhibitory activities of sorafenib on histone deacetylases in hepatocellular carcinoma cells.
Tsang-Pai Liu, Yi-Han Hong, Pei-Ming Yang

Oncotarget· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In silico and experimental analyses predict the therapeutic value of an EZH2 inhibitor GSK343 against hepatocellular carcinoma through the induction of metallothionein genes.
Tsang-Pai Liu, Yi-Han Hong, Kwang-Yi Tung, Pei-Ming Yang

Oncoscience· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating matrix metalloproteinase-2 and -9 enzyme activities in the children with ventricular septal defect.
Kun-Shan Cheng, Yan-Chiou Liao, Mu-Yuan Chen, Tang-Ching Kuan, Yi-Han Hong

Int J Biol Sci· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Angiotensin II downregulates ACE2-mediated enhancement of MMP-2 activity in human cardiofibroblasts.
Tang-Ching Kuan, Mu-Yuan Chen, Yan-Chiou Liao, Li Ko, Yi-Han Hong

Biochem Cell Biol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis